Tough year ahead as generics take bite out of market: Teva

14-02-2019

Tough year ahead as generics take bite out of market: Teva

JHVEPhoto / Shutterstock.com

Israel-based Teva has predicted 2019 will be a tough year, with lower revenue and profit, as the company faces generic competition for two of its top-selling drugs.


Teva, generics, revenues, full-year results, generic competition, Copaxone, ProAir, generic sales, Kåre Schultz, research and development, R&D

LSIPR